Table 2.
Patient demographics of included studies
| Study | Follow-up duration | Sex (n, male/female) | Age (years) | BMI (kg/m2) |
|---|---|---|---|---|
| Shon et al. 2023 [20] |
26.2 ± 8.1 months (SD), 27.9 ± 8.7 months (SD + PCHCA) |
7/44 (SD), 9/42 (SD + PCHCA) |
55.8 ± 5.3 (SD), 55.3 ± 5.5 (SD + PCHCA) |
26.9 ± 3.5 (SD), 26.3 ± 3.5 (SD + PCHCA) |
| Kim et al. 2023 [21] |
27.8 ± 3.6 months (SVF), 28.2 ± 4.1 months (hUCB-MSC) |
8/17 (SVF), 9/16 (hUCB-MSC) |
56.0 ± 4.8 (SVF), 56.4 ± 6.0 (hUCB-MSC) |
26.1 ± 2.9 (SVF), 26.5 ± 2.7 (hUCB-MSC) |
| Wu et al. 2023 [22] | 14.6 ± 5.8 months | 11/39 | 56 ± 3.4 | 23.4 ± 3.8 |
| Park et al. 2023 [23] | 2.9 years (range 1–6 years) | 3/9 | 54.3 ± 7.8 | 25.9 ± 2.8 |
| Lee et al. 2023 [24] | 26.5 ± 9.1 months | 21/44 | 58 ± 9 | 27.5 ± 3.1 |
| Yang et al. 2022 [25] |
34.2 ± 8.4 months (BMAC), 31.0 ± 6.0 months (hUCB-MSC) |
17/38 (BMAC), 13/42 (hUCB-MSC) |
55.0 ± 7.3 (BMAC), 56.4 ± 5.3 (hUCB-MSC) |
27.2 ± 3.9 (BMAC), 26.8 ± 3.2 (hUCB-MSC) |
| Kim et al. 2022 [34] |
26.0 ± 8.7 months (RKL), 26.1 ± 8.5 months (no RKL) |
3/14 (RKL), 11/94 (no RKL) |
55.1 ± 4.3 (RKL), 56.1 ± 5.1 (no RKL) |
25.8 ± 1.9 (RKL), 25.9 ± 2.7 (no RKL) |
| Otsuki et al. 2022 [26] | 31.0 ± 9.1 months | 59/83 | 63.2 ± 9.6 | 25.3 ± 4.3 |
| Jin et al. 2021 [32] |
36.5 ± 8.2 months (MFX), 33.6 ± 6.6 months (BMAC) |
13/30 (MFX), 11/37 (BMAC) |
55.8 ± 4.4 (MFX), 56.9 ± 6.1 (BMAC) |
25.8 ± 2.9 (MFX), 25.8 ± 3.1 (BMAC) |
| Chung et al. 2021 [27] | 1.7 years (range 1.0–3.5 years) | not mentioned | 56.6 (range 43–65) | 25.8 (range 20.9–33.2) |
| Iida et al. 2021 [28] | 14.1 ± 4.5 months | 0/8 | 57.6 ± 5.2 | 26.8 ± 1.8 |
| Song et al. 2020 [29] | 3.0 years | 95/30 | 58.3 ± 6.8 | 25.6 ± 2.7 |
| Lee et al. 2019 [30] |
2.0 ± 0.2 years (MFX), 1.9 ± 0.1 years (no procedure) |
37/20 (MFX), 7/23 (no procedure) |
57.0 ± 5.4 (MFX), 57.0 ± 6.5 (no procedure) |
26.5 ± 3.6 (MFX), 26.4 ± 3.3 (no procedure) |
| Kim et al. 2017 [35] | 1.0 year |
0/14 (MFX), 1/13 (MFX + collagen) |
55.7 ± 5.9 (MFX), 55.4 ± 4.8 (MFX + collagen) |
24.1 ± 2.8 (MFX), 24.4 ± 2.7 (MFX + collagen) |
| Kumagai et al. 2017 [31] | 20.8 ± 6.5 months | 30/70 | 66.1 ± 7.7 | 24.9 ± 3.3 |
| Jung et al. 2015 [33] |
25.7 ± 8.3 months (SD), 24.1 ± 5.7 months (no procedure) |
3/27 (SD), 3/28 (no procedure) |
61.5 ± 7.5 (SD), 58.6 ± 6.9 (no procedure) |
25.8 ± 2 (SD), 25.6 ± 2.3 (no procedure) |
MOW medial open wedge, SD subchondral drilling, PCHCA particulated costal hyaline cartilage allograft, SVF stromal vascular fraction, hUCB-MSC human umbilical cord blood-derived mesenchymal stem cell, BMAC bone marrow aspirate concentrate, RKL radiological kissing lesion, MFX microfracture